Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? 5

• Material Type: 博士論文
• ISSN: 2005-0399
• Title: Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
• Volume: 30 5
• Author/Editor: 米岡, 完; YONEOKA, Yutaka
• Author Heading: 米岡, 完; YONEOKA, Yutaka
• Publication, Distribution, etc.: Asian Society of Gynecologic Oncology
• Publication Date: 2019-09
• Publication Date (W3CDTF): 2019-09
• Periodical title: Journal of J Gynecologic Oncology
• Degree grantor/type: 滋賀医科大学
• Date Granted: 2021-03-09
• Date Granted (W3CDTF): 2021-03-09
• Dissertation Number: 乙第455号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 乙第455号
• Text Language Code: eng
• Subject Heading: CA-125 Antigen; Cytoreduction Surgical Procedures; Neoadjuvant Therapy; Ovarian Neoplasm
• Target Audience: 一般
• Note (General): pdf; Objective:To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete resection cannot be achieved by IDS, debulking surgery is performed after administering additional 3 cycles of chemotherapy without postoperative chemotherapy (Add-C group). We evaluated the survival outcomes of the Add-C group and determined their serum cancer antigen 125 (CA125) levels to predict complete surgery.; Methods:A retrospective chart review of all stage III and IV ovarian, fallopian tube, and peritoneal cancer patients treated with NAC in 2007-2016 was conducted.; Results:About 117 patients comprised the IDS group and 26 comprised the Add-C group. Univariate and multivariate analyses revealed that Add-C group had an equivalent effect on progression-free survival (PFS; p=0.09) and overall survival (OS; p=0.94) compared with the IDS group. Multivariate analysis revealed that patients who developed residual disease after surgery had worse PFS (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.45-3.28) and OS (HR=2.33; 95% CI=1.43-3.79), and those who received <6 cycles of chemotherapy had worse PFS (HR=5.30; 95% CI=2.56-10.99) and OS (HR=3.05; 95% CI=1.46-6.38). The preoperative serum CA125 cutoff level was 30 U/mL based on Youden index method.; Conclusions:Administering 3 additional cycles of chemotherapy followed by debulking surgery exhibited equivalent effects on survival as IDS followed by 3 cycles of postoperative chemotherapy. Preoperative serum CA125 levels of ≤30 U/mL may be a useful predictor of achieving complete surgery.; Thesis or Dissertation; 令和2年度; 10.3802/jgo.2019.30.e81; 博士論文要旨
• DOI: info:doi/10.3802/jgo.2019.30.e81; https://doi.org/info:doi/10.3802/jgo.2019.30.e81
• Persistent ID (NDL): info:ndljp/pid/11710937; https://dl.ndl.go.jp/pid/11710937
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2021-08-09T17:15:52+09:00
• Date Created (W3CDTF): 2021-07-14
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Related Material (URI): http://hdl.handle.net/10422/00013005
• Periodical Title (URI): http://hdl.handle.net/10422/00013044; https://shiga-med.repo.nii.ac.jp/records/3946
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp

Table of Contents

2023-09-08 再収集